scholarly journals Diabetic kidney disease: new treatment options

2013 ◽  
Vol 3 (2) ◽  
pp. 123-130
Author(s):  
Merlin C Thomas
Keyword(s):  
Kidney Disease ◽  
Diabetic Kidney Disease ◽  
Treatment Options ◽  
Diabetic Kidney ◽  
New Treatment

scholarly journals The incretin pathway as a therapeutic target in diabetic kidney disease: a clinical focus on GLP-1 receptor agonists

2019 ◽  
Vol 10 ◽  
pp. 204201881986539 ◽  
Author(s):  
Michaël J. B. van Baar ◽  
Annemarie B. van der Aart ◽  
Klaas Hoogenberg ◽  
Jaap A. Joles ◽  
Hiddo J. L. Heerspink ◽  
...  
Keyword(s):  
Kidney Disease ◽  
Diabetic Kidney Disease ◽  
Treatment Options ◽  
Diabetic Kidney ◽  
Receptor Agonists ◽  
Glucose Levels ◽  
Glucagon Like Peptide ◽  
New Treatment ◽  
End Stage ◽  
Increases In Risk

Diabetic kidney disease (DKD) remains the main cause for chronic kidney disease (CKD) and end-stage kidney disease (ESKD) worldwide. Both CKD and ESKD lead to major increases in risk of cardiovascular disease and death in people with diabetes. Despite optimal management of lifestyle, glucose levels and hypertension, residual risk remains high, indicating that additional therapies to mitigate the burden of the disease are desired. In past decades, new treatment options for the management of diabetes have emerged, of which some have showed promising renoprotective potential. This review discusses current understanding of the renal effects of glucagon-like peptide receptor agonists and their potential use in prevention and treatment of DKD.

scholarly journals SGLT-2 Inhibition: A Potential New Treatment for Diabetic Kidney Disease?

Nephron ◽  
2017 ◽  
Vol 137 (1) ◽  
pp. 64-67 ◽  
Author(s):  
Robert D. Toto
Keyword(s):  
Kidney Disease ◽  
Diabetic Kidney Disease ◽  
Diabetic Kidney ◽  
New Treatment

scholarly journals Glomerular Diseases in Diabetic Patients: Implications for Diagnosis and Management

2021 ◽  
Vol 10 (9) ◽  
pp. 1855
Author(s):  
Nestor Oliva-Damaso ◽  
José María Mora-Gutiérrez ◽  
Andrew S. Bomback
Keyword(s):  
Kidney Disease ◽  
Diabetic Kidney Disease ◽  
Treatment Strategies ◽  
Glomerular Disease ◽  
Diabetic Patients ◽  
Glomerular Diseases ◽  
Diabetic Kidney ◽  
Sodium Glucose Cotransporter ◽  
Patients With Diabetes ◽  
New Treatment

The prevalence of diabetes continues to rise worldwide. In addition to rising rates of diabetic kidney disease, we are also seeing a parallel rise in nondiabetic kidney disease among patients with diabetes. These nondiabetic lesions include focal segmental glomerulosclerosis, IgA nephropathy, membranous nephropathy, and other glomerular diseases. The management of diabetic kidney disease is rapidly evolving to include, beyond glycemic control and renin angiotensin inhibition, the use of sodium-glucose cotransporter 2 (SGLT2) inhibitors and mineralocorticoid receptor antagonists. These and other new treatment strategies should be applicable to managing glomerular disease in diabetic patients to reduce toxicities associated with immunosuppression and, in particular, corticosteroids. The prevalence of glomerular disease in diabetic patients is underappreciated. Diagnosis and appropriately treating these diseases remain an important avenue to modify kidney outcomes in diabetic patients.

scholarly journals Therapeutic Advances in Diabetic Nephropathy

2022 ◽  
Vol 11 (2) ◽  
pp. 378
Author(s):  
Hanny Sawaf ◽  
George Thomas ◽  
Jonathan J. Taliercio ◽  
Georges Nakhoul ◽  
Tushar J. Vachharajani ◽  
...  
Keyword(s):  
Kidney Disease ◽  
Diabetic Kidney Disease ◽  
Treatment Options ◽  
The United States ◽  
Additional Treatment ◽  
Diabetic Kidney ◽  
Raas Blockade ◽  
Risk Factor Modification ◽  
Glucagon Like Peptide 1 ◽  
End Stage

Diabetic kidney disease (DKD) is the most common cause of end-stage kidney disease (ESKD) in the United States. Risk factor modification, such as tight control of blood glucose, management of hypertension and hyperlipidemia, and the use of renin–angiotensin–aldosterone system (RAAS) blockade have been proven to help delay the progression of DKD. In recent years, new therapeutics including sodium-glucose transport protein 2 (SGLT2) inhibitors, endothelin antagonists, glucagon like peptide-1 (GLP-1) agonists, and mineralocorticoid receptor antagonists (MRA), have provided additional treatment options for patients with DKD. This review discusses the various treatment options available to treat patients with diabetic kidney disease.

scholarly journals Roles of mTOR in Diabetic Kidney Disease

Antioxidants ◽  
2021 ◽  
Vol 10 (2) ◽  
pp. 321
Author(s):  
Mako Yasuda-Yamahara ◽  
Shinji Kume ◽  
Hiroshi Maegawa
Keyword(s):  
Kidney Disease ◽  
Diabetic Kidney Disease ◽  
Cell Injury ◽  
Nutrient Sensing ◽  
Diabetic Patients ◽  
Diabetic Kidney ◽  
Number Of Patients ◽  
New Treatment ◽  
Stage Renal Disease ◽  
End Stage

Diabetic kidney disease (DKD) is the leading cause of end-stage renal disease and the number of patients affected is increasing worldwide. Thus, there is a need to establish a new treatment for DKD to improve the renal prognosis of diabetic patients. Recently, it has shown that intracellular metabolic abnormalities are involved in the pathogenesis of DKD. In particular, the activity of mechanistic target of rapamycin complex 1 (mTORC1), a nutrient-sensing signaling molecule, is hyperactivated in various organs of diabetic patients, which suggests the involvement of excessive mTORC1 activation in the pathogenesis of diabetes. In DKD, hyperactivated mTORC1 may be involved in the pathogenesis of podocyte damage, which causes proteinuria, and tubular cell injury that decreases renal function. Therefore, elucidating the role of mTORC1 in DKD and developing new therapeutic agents that suppress mTORC1 hyperactivity may shed new light on DKD treatments in the future.

scholarly journals Normoalbuminuric chronic kidney disease in diabetes

2018 ◽  
Vol 90 (10) ◽  
pp. 94-98
Author(s):  
V V Klimontov ◽  
A I Korbut
Keyword(s):  
Chronic Kidney Disease ◽  
Kidney Disease ◽  
Diabetic Kidney Disease ◽  
Interstitial Fibrosis ◽  
Treatment Options ◽  
Practical Importance ◽  
Future Research ◽  
Diabetic Patients ◽  
Tubular Damage ◽  
Diabetic Kidney

Urinary albumin excretion (UAE) is widely used in clinical practice as indicator of diabetic kidney disease. According to the classical concept of the natural course of diabetic nephropathy, an increase in UAE usually precedes a decline in renal function. Meanwhile, a growing body of evidences indicates a high prevalence of normoalbuminuric chronic kidney disease (NA-CKD) in diabetic subjects, especially among patients with type 2 diabetes. An increase in NA-CKD prevalence can be results of improved glucose, blood pressure, and lipid control, widespread use of renin-angiotensin system blockers, and smoking cessation. It was shown that NA-CKD is more prevalent among women and is associated with arterial hypertension and coronary artery disease. The renal structure in subjects with NA-CKD is more heterogeneous when compared to patients with increased albuminuria, wherein interstitial changes and arteriolosclerosis could be the principal morphological findings, while signs of glomerulopathy may be absent. The prognostic value of NA-CKD needs to be clarified. It was shown that NA-CKD increases the risk of myocardial infarction, stroke and cardiovascular death in patients with diabetes. The search for alternative diagnostic markers for detecting of diabetic kidney disease in the absence of albuminuria, is of practical importance. The evaluations of the markers of tubular damage and interstitial fibrosis, as well as proteomic approaches, are considered as perspective diagnostic and prognostic options in NA-CKD. The study of pathogenesis, pathology, clinical course of NA-CKD in diabetic patients, as well as the development of more specific diagnostic and treatment options is a challenge for future research.

Systems Medicine Derived Biomarkers to Assess How Canagliflozin Delays Progression of Diabetic Kidney Disease

Diabetes ◽  
2018 ◽  
Vol 67 (Supplement 1) ◽  
pp. 1126-P
Author(s):  
HIDDO LAMBERS. HEERSPINK ◽  
PAUL PERCO ◽  
JOHANNES LEIERER ◽  
MICHAEL K. HANSEN ◽  
ANDREAS HEINZEL ◽  
...  
Keyword(s):  
Kidney Disease ◽  
Diabetic Kidney Disease ◽  
Systems Medicine ◽  
Diabetic Kidney

Factors Related to the High Prevalence of Diabetic Kidney Disease in Ecuador-Update for Health Policy Makers

Diabetes ◽  
2018 ◽  
Vol 67 (Supplement 1) ◽  
pp. 526-P
Author(s):  
MARIANA E. GUADALUPE ◽  
GRACIELA B. ALVAREZ CONDO ◽  
FANNY E. VERA LORENTI ◽  
BETTY J. PAZMIÑO GOMEZ ◽  
EDGAR I. RODAS NEIRA ◽  
...  
Keyword(s):  
Health Policy ◽  
Kidney Disease ◽  
Diabetic Kidney Disease ◽  
Policy Makers ◽  
Diabetic Kidney ◽  
High Prevalence
Sign in / Sign up

Export Citation Format

Share Document